[8-K] Quince Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

Quince Therapeutics, Inc. reported that on August 11, 2025 it announced its financial results for the quarter ended June 30, 2025 and provided recent business highlights. The company states the related press release is furnished as Exhibit 99.1 to this Current Report. The filing explicitly says the information (including Exhibit 99.1) is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act. No financial figures or business-detail text from the press release are included in the provided document. The report is signed by Dirk Thye, Chief Executive Officer and Chief Medical Officer.

Positive

• Disclosure provided: The company publicly announced its quarter ended June 30, 2025 results and business highlights.
• Exhibit furnished: The press release is formally furnished as Exhibit 99.1 to the Current Report.

Negative

• No financial details included: The 8-K text does not contain revenue, income, cash, or other numerical results.
• Exhibit not included here: Because the press release content is not provided in this document, the filing does not allow an assessment of operating or financial performance.
• Furnished, not filed: The filing explicitly states the information is furnished and shall not be deemed filed under Section 18 of the Exchange Act, which limits statutory liability for the disclosure.

Insights

Financial Analyst

TL;DR: Routine 8-K announcing Q2 2025 results; press release is furnished but no financial data appears in this filing.

The filing notifies investors that Quince announced results for the quarter ended June 30, 2025 and furnished a press release as Exhibit 99.1. Because the press release text or numerical results are not included here, this 8-K does not permit evaluation of revenue, earnings, cash position, or operating trends. The disclosure is procedural and informational; material conclusions about performance require review of the furnished exhibit or the company’s full earnings release.

Corporate Governance Expert

TL;DR: Formal disclosure filed; exhibit is furnished, limiting Section 18 liability, and the filing is signed by the CEO/CMO.

The report follows standard Form 8-K practice by furnishing the press release and explicitly stating it is not "filed" for purposes of Section 18 of the Exchange Act. That distinction is meaningful for legal liability around the disclosure. The signature of Dirk Thye, as CEO and Chief Medical Officer, is included, confirming authorized company attestation of the filing. Absent the exhibit text, governance review cannot assess accuracy or completeness of the announced results.

false000166277400016627742025-08-112025-08-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2025

Quince Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-38890	90-1024039
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
601 Gateway Boulevard Suite 1250
South San Francisco, California				94080
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (415) 910-5717

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		QNCX		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 11, 2025, Quince Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2025 and provided recent business highlights. A copy of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press release issued by Quince Therapeutics, Inc. dated August 11, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			QUINCE THERAPEUTICS, INC.
Date:	August 11, 2025	By:	/s/ Dirk Thye
		Name: Title:	Dirk Thye Chief Executive Officer and Chief Medical Officer

FAQ

What did Quince Therapeutics (QNCX) disclose in this 8-K?

The company announced its financial results for the quarter ended June 30, 2025 and provided recent business highlights; the related press release is furnished as Exhibit 99.1.

Is the press release included or filed with the 8-K?

The press release is furnished as Exhibit 99.1; the filing states it shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.

Does this 8-K include financial numbers for Q2 2025?

No. The provided 8-K text does not contain any financial figures or detailed results.

Who signed the 8-K for Quince Therapeutics?

The form is signed by Dirk Thye, identified as Chief Executive Officer and Chief Medical Officer, dated August 11, 2025.

Where is Quince Therapeutics (QNCX) stock listed?

The filing shows Common Stock, par value $0.001 per share trading as QNCX on the Nasdaq Global Select Market.